Gabriel Katz1, Sharon Blum2, Omer Leeva3, Ruth Axer-Siegel3, Joseph Moisseiev2, Gili Tesler3, Rita Ehrlich3. 1. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel. gabrielkatz.dr@gmail.com. 2. Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, 52621, Israel. 3. Ophthalmology Department, Rabin Medical Center, Petah Tikva, Israel.
Abstract
PURPOSE: The European Society of Cataract & Refractive Surgeons (ESCRS) study reported a decrease in endophthalmitis rates from 0.34 % to 0.08 % with the use of intracameral cefuroxime. The purpose of this study was to compare the endophthalmitis rates before and after the introduction of intracameral cefuroxime (ICC) routinely at the end of cataract surgery. METHODS: A retrospective consecutive cohort study. We compared the rates of endophthalmitis between the years 2000-2006, and the years 2007-2014, after the pivotal publication of the ESCRS. Data collected included age, gender, culture results, initial and final visual acuity, and complications. Only patients that presented with endophthalmitis following cataract surgery performed at the two centers were included. RESULTS: Twenty-two cases of endophthalmitis occurred between the years 2000 and 2006, out of 26,663 cataract operations performed at the two centers, a rate of 0.083 %. Ten cases occurred between the years 2007 and 2014 out of 29,431 cataract operations, a rate of 0.034 %. The difference was statistically significant (p = 0.03) CONCLUSIONS: The introduction of prophylactic use of intracameral cefuroxime was associated with a significant reduction in post-operative endophthalmitis rates in our centers. We strongly recommend adoption of this routine by for all cataract operations except when contraindicated.
PURPOSE: The European Society of Cataract & Refractive Surgeons (ESCRS) study reported a decrease in endophthalmitis rates from 0.34 % to 0.08 % with the use of intracameral cefuroxime. The purpose of this study was to compare the endophthalmitis rates before and after the introduction of intracameral cefuroxime (ICC) routinely at the end of cataract surgery. METHODS: A retrospective consecutive cohort study. We compared the rates of endophthalmitis between the years 2000-2006, and the years 2007-2014, after the pivotal publication of the ESCRS. Data collected included age, gender, culture results, initial and final visual acuity, and complications. Only patients that presented with endophthalmitis following cataract surgery performed at the two centers were included. RESULTS: Twenty-two cases of endophthalmitis occurred between the years 2000 and 2006, out of 26,663 cataract operations performed at the two centers, a rate of 0.083 %. Ten cases occurred between the years 2007 and 2014 out of 29,431 cataract operations, a rate of 0.034 %. The difference was statistically significant (p = 0.03) CONCLUSIONS: The introduction of prophylactic use of intracameral cefuroxime was associated with a significant reduction in post-operative endophthalmitis rates in our centers. We strongly recommend adoption of this routine by for all cataract operations except when contraindicated.
Authors: Maria Carmen García-Sáenz; Alfonso Arias-Puente; Gil Rodríguez-Caravaca; Josefina B Bañuelos Journal: J Cataract Refract Surg Date: 2010-02 Impact factor: 3.351
Authors: Mehran Taban; Ashley Behrens; Robert L Newcomb; Matthew Y Nobe; Golnaz Saedi; Paula M Sweet; Peter J McDonnell Journal: Arch Ophthalmol Date: 2005-05
Authors: Andrew F Riley; Tahira Y Malik; Christina N Grupcheva; Michael J Fisk; Jennifer P Craig; Charles N McGhee Journal: Br J Ophthalmol Date: 2002-02 Impact factor: 4.638
Authors: Patrick Yu-Wai-Man; Stephen J Morgan; Anthony J Hildreth; David H Steel; David Allen Journal: J Cataract Refract Surg Date: 2008-03 Impact factor: 3.351
Authors: Randy C Bowen; Andrew Xingyu Zhou; Sailaja Bondalapati; Thomas W Lawyer; Karisa B Snow; Patrick R Evans; Tyler Bardsley; Mary McFarland; Matthew Kliethermes; Dallas Shi; Christina A Mamalis; Tom Greene; Christopher J Rudnisky; Balamurali Krishna Ambati Journal: Br J Ophthalmol Date: 2018-01-11 Impact factor: 4.638